
  
    
      
        Background_NNP
        One_CD mechanism_NN by_IN which_WDT tumors_NNS evade_VB immune_JJ destruction_NN
        is_VBZ through_IN cytokine_NN production_NN or_CC induction_NN [_NN 1_CD ]_NN ._.
        Prostaglandin_NNP E-_NNP 2_CD (_( PGE-_NNP 2_LS )_) ,_, constitutively_RB produced_VBN by_IN many_JJ
        NSCLC_NNP has_VBZ been_VBN identified_VBN as_IN one_CD factor_NN that_WDT has_VBZ direct_JJ
        immunosuppressive_JJ properties_NNS and_CC is_VBZ known_VBN to_TO induce_VB IL_NNP 10_CD in_IN
        mononuclear_NN cells_NNS [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ._. IL_NNP 10_CD is_VBZ a_DT dominant_JJ
        immunosuppressive_JJ cytokine_NN found_VBD in_IN the_DT NSCLC_NNP environment_NN
        known_VBN to_TO directly_RB affect_VB T_NN cell-mediated_JJ immunity_NN [_NN 2_CD 3_CD 4_CD 5_CD
        6_CD 7_CD 8_CD 9_CD 10_CD 11_CD 12_CD ]_NN ._. Both_DT PGE-_NNP 2_CD and_CC IL_NNP 10_CD have_VBP been_VBN shown_VBN to_TO
        suppress_VB antigen_NN presentation_NN ,_, to_TO suppress_VB cytotoxic_JJ T_NN cell_NN
        (_( CTL_NNP )_) responses_NNS ,_, and_CC to_TO inhibit_VB cytokine_NN production_NN by_IN T_NN
        cells_NNS and_CC antigen_NN presenting_VBG cells_NNS ,_, perhaps_RB most_RBS
        importantly_RB IL_NNP 12_CD ,_, that_WDT plays_VBZ a_DT central_JJ role_NN in_IN initiation_NN
        and_CC potentiation_NN of_IN cellular_JJ immune_JJ responses_NNS [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD
        ]_NN ,_, [_NN 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD 17_CD 18_CD 19_CD ]_NN ._. We_PRP asked_VBD whether_IN PGE-_NNP 2_CD
        levels_NNS and_CC /_NN or_CC IL_NNP 10_CD levels_NNS were_VBD elevated_VBD in_IN plasma_NN of_IN NSCLC_NNP
        patients_NNS ,_, whether_IN monocytes_NNS from_IN NSCLC_NNP patients_NNS produce_VBP
        more_JJR IL_NNP 10_CD than_IN normals_NNS ,_, and_CC whether_IN there_EX was_VBD correlation_NN
        within_IN our_PRP$ findings_NNS ._. As_IN an_DT additional_JJ 
        in_IN vitro_NN correlate_VBP ,_, we_PRP evaluated_VBD
        differences_NNS in_IN IL_NNP 10_CD production_NN by_IN normal_JJ adherent_NN
        peripheral_JJ blood_NN mononuclear_NN cells_NNS cultured_JJ in_IN conditioned_VBN
        media_NNS from_IN cell_NN lines_NNS that_WDT produce_VBP variable_JJ amounts_NNS of_IN
        PGE-_NNP 2_CD ._.
      
      
        Results_NNS
        
          PGE-_NNP 2_CD produced_VBN by_IN tumor_NN cell_NN lines_NNS correlated_JJ with_IN
          IL_NNP 10_CD production_NN by_IN normal_JJ donor_NN adherent_NN PBMC_NNP
          To_TO confirm_VB observations_NNS from_IN the_DT literature_NN ,_,
          supernatants_NNS from_IN 6_CD different_JJ NSCLC_NNP cell_NN lines_NNS producing_VBG
          variable_JJ amounts_NNS of_IN PGE-_NNP 2_CD (_( ranging_VBG from_IN 100_CD pg_NN /_NN ml_NN /_NN 5_CD ×_NN 10_CD
          5_CD cells_NNS to_TO >_NN 50_CD ,_, 000_CD pg_NN /_NN ml_NN /_NN 5_CD ×_NN 10_CD 5_CD cells_NNS )_) were_VBD compared_VBN
          directly_RB for_IN their_PRP$ ability_NN to_TO induce_VB IL_NNP 10_CD in_IN adherent_NN
          mononuclear_NN cells_NNS ._. Each_DT cell_NN line_NN induced_VBD IL_NNP 10_CD in_IN
          adherent_NN mononuclear_NN cells_NNS that_WDT was_VBD greater_JJR than_IN control_NN ._.
          This_DT relative_JJ increase_NN in_IN IL_NNP 10_CD correlated_JJ with_IN PGE-_NNP 2_CD
          produced_VBN by_IN each_DT cell_NN line_NN (_( p_NN <_NN 0_CD ._. 05_CD )_) ._. (_( Figure_NN 1_LS )_) ._.
        
        
          PGE-_NNP 2_CD levels_NNS in_IN plasma_NN of_IN individuals_NNS with_IN
          NSCLC_NNP
          Two_CD separate_JJ assays_NNS yielded_VBD similar_JJ elevations_NNS in_IN
          plasma_NN levels_NNS of_IN PGE_NNP 2_CD above_IN normals_NNS ._. Each_DT assay_NN used_VBD
          different_JJ sets_NNS of_IN normals_NNS for_IN comparison_NN ._. Significant_JJ
          differences_NNS were_VBD seen_VBN when_WRB comparing_VBG measurements_NNS from_IN 38_CD
          NSCLC_NNP samples_NNS to_TO 9_CD normals_NNS (_( 234_CD +_NN /_NN -_: 40_CD vs_NNS ._. 519_CD +_NN /_NN -_: 54_CD ;_: p_NN =_SYM
          0_CD ._. 0167_CD )_) and_CC 27_CD NSCLC_NNP patient_NN samples_NNS to_TO 16_CD normals_NNS
          (_( 846_CD +_NN /_NN -_: 62_CD vs_NNS ._. 1838_CD +_NN /_NN -_: 213_CD ;_: p_NN =_SYM 0_CD ._. 0011_CD )_) (_( Figure_NN 2_LS )_) ._.
          Absolute_JJ measures_NNS of_IN PGE-_NNP 2_CD differed_VBD between_IN assays_NNS that_WDT
          prevented_VBD the_DT pooling_VBG of_IN results_NNS ;_: relative_JJ values_NNS may_MD
          reflect_VB differences_NNS in_IN sample_NN handling_NN or_CC assay_NN
          conditions_NNS ,_, or_CC differences_NNS in_IN ELISA_NNP kits_NNS themselves_PRP ._.
          Plasma_NNP IL_NNP 10_CD levels_NNS measured_VBN in_IN 29_CD patient_NN samples_NNS were_VBD
          not_RB significantly_RB elevated_VBD above_IN controls_NNS (_( 6_CD ._. 6_CD ±_NN 4_CD ._. 6_CD vs_NNS ._.
          3_CD ._. 9_CD ±_NN 3_CD ._. 6_CD ;_: p_NN >_NN 0_CD ._. 1_CD ;_: not_RB shown_VBN )_) ._. PGE-_NNP 2_CD levels_NNS did_VBD not_RB
          correlate_VBP with_IN stage_NN or_CC histology_NN (_( p_NN >_NN 0_CD ._. 1_CD all_DT
          comparisons_NNS )_) ._.
        
        
          Cytokine_NNP profiles_NNS of_IN adherent_NN mononuclear_NN cells_NNS
          from_IN NSCLC_NNP patients_NNS
          Adherent_NNP cells_NNS ,_, predominantly_RB mononuclear_NN phagocytes_NNS ,_,
          from_IN 13_CD individuals_NNS were_VBD evaluated_VBN for_IN IL_NNP 10_CD production_NN ._.
          Data_NNP show_NN adherent_NN mononuclear_NN cells_NNS from_IN NSCLC_NNP patients_NNS
          produced_VBD baseline_NN levels_NNS of_IN IL_NNP 10_CD significantly_RB greater_JJR
          than_IN those_DT of_IN normal_JJ volunteers_NNS (_( 40_CD ±_NN 25_CD vs_NNS ._. 574_CD ±_NN 127_CD ;_: p_NN
          <_NN 0_CD ._. 01_CD ;_: Figure_NN 3_LS )_) ._. IL_NNP 10_CD production_NN did_VBD not_RB correlate_VBP
          with_IN stage_NN or_CC histology_NN (_( not_RB shown_VBN )_) ._.
        
        
          Correlation_NNP of_IN PGE-_NNP 2_CD levels_NNS and_CC IL_NNP 10_CD production_NN
          from_IN adherent_NN mononuclear_NN cells_NNS
          Paired_NNP comparisons_NNS of_IN plasma_NN PGE-_NNP 2_CD levels_NNS and_CC
          mononuclear_NN cell_NN IL_NNP 10_CD was_VBD possible_JJ in_IN 11_CD patient_NN samples_NNS ._.
          Paired_NNP comparisons_NNS in_IN patient_NN sample_NN did_VBD not_RB reach_VB
          statistical_JJ significance_NN (_( p_NN >_NN 0_CD ._. 1_LS )_) ,_, although_IN in_IN a_DT
          subset_NN of_IN 9_CD patients_NNS ,_, excluding_VBG 2_CD samples_NNS with_IN the_DT
          highest_JJS PGE-_NNP 2_CD levels_NNS ,_, a_DT positive_JJ correlation_NN of_IN PGE-_NNP 2_CD
          levels_NNS and_CC IL_NNP 10_CD production_NN was_VBD apparent_JJ (_( p_NN <_NN 0_CD ._. 05_CD ;_:
          Figure_NN 4_LS )_) ._. There_EX was_VBD no_DT simple_JJ explanation_NN for_IN these_DT
          outliers_NNS ,_, nor_CC rationale_NN for_IN excluding_VBG these_DT samples_NNS ._.
          There_EX was_VBD a_DT significant_JJ correlation_NN between_IN PGE-_NNP 2_CD levels_NNS
          and_CC IL_NNP 10_CD production_NN in_IN normal_JJ samples_NNS (_( p_NN <_NN 0_CD ._. 05_CD )_) ,_, but_CC
          combining_VBG normals_NNS and_CC patient_NN data_NNS did_VBD not_RB strengthen_VB the_DT
          statistical_JJ observations_NNS ._.
        
      
      
        Discussion_NNP
        COX-_NNP 2_CD is_VBZ an_DT inducible_JJ enzyme_NN upregulated_JJ in_IN inflammatory_JJ
        states_NNS [_NN 20_CD 21_CD ]_NN ._. Notably_RB ,_, many_JJ NSCLC_NNP and_CC what_WP have_VBP been_VBN
        characterized_VBN as_IN "_'' premalignant_NN "_'' lung_NN lesions_NNS have_VBP been_VBN
        shown_VBN to_TO constitutively_RB express_VB the_DT COX-_NNP 2_CD enzyme_NN and_CC
        produce_VB prostaglandin_NN E-_NNP 2_CD (_( PGE-_NNP 2_LS )_) ,_, the_DT primary_JJ product_NN of_IN
        the_DT COX-_NNP 2_CD pathway_NN [_NN 22_CD 23_CD 24_CD 25_CD 26_CD ]_NN ._. Importantly_NNP ,_, PGE-_NNP 2_CD
        production_NN by_IN tumor_NN cells_NNS has_VBZ been_VBN linked_VBN to_TO tumor-induced_JJ
        immunosuppression_NN in_IN NSCLC_NNP [_NN 2_CD 3_CD 4_CD 5_CD ]_NN ._. PGE-_NNP 2_CD has_VBZ been_VBN
        shown_VBN to_TO directly_RB suppress_VB T_NN cell_NN mediated_JJ immunity_NN ,_, the_DT
        primary_JJ effector_NN against_IN tumor_NN cells_NNS ,_, at_IN a_DT variety_NN of_IN
        levels_NNS [_NN 2_CD 3_CD 4_CD 5_CD 6_CD 7_CD ]_NN ._. Further_RB ,_, PGE-_NNP 2_CD has_VBZ been_VBN shown_VBN to_TO
        induce_VB the_DT IL_NNP 10_CD in_IN mononuclear_NN cells_NNS [_NN 4_CD 5_CD ]_NN ._. IL_NNP 10_CD is_VBZ a_DT
        prominent_JJ immunosuppressive_JJ cytokine_NN that_WDT may_MD have_VB a_DT
        dominant_JJ role_NN in_IN preventing_VBG innate_JJ antitumor_NN responses_NNS in_IN
        the_DT NSCLC_NNP environment_NN [_NN 2_CD 3_CD 4_CD 5_CD ]_NN ,_, [_NN 8_CD 9_CD 10_CD 11_CD 12_CD 13_CD 14_CD 15_CD
        16_CD 17_CD 18_CD 19_CD ]_NN ._. Among_IN myriad_JJ suppressive_JJ effects_NNS on_IN T_NN cells_NNS
        and_CC antigen_NN presenting_VBG cells_NNS ,_, IL_NNP 10_CD is_VBZ known_VBN to_TO inhibit_VB IL_NNP 12_CD
        production_NN [_NN 14_CD 15_CD 16_CD 17_CD 18_CD ]_NN ._. IL_NNP 12_CD plays_VBZ a_DT key_JJ role_NN in_IN
        the_DT initiation_NN and_CC potentiation_NN of_IN cellular_JJ immune_JJ
        responses_NNS and_CC alteration_NN of_IN the_DT IL_NNP 12_CD producing_VBG function_NN in_IN
        circulating_VBG mononuclear_NN phagocytes_NNS may_MD be_VB a_DT critical_JJ factor_NN
        in_IN suppressed_VBN T_NN cell_NN immunity_NN to_TO NSCLC_NNP [_NN 27_CD 28_CD ]_NN ._.
        We_PRP evaluated_VBD both_DT PGE-_NNP 2_CD and_CC IL_NNP 10_CD in_IN plasma_NN of_IN NSCLC_NNP
        patients_NNS finding_VBG only_RB PGE-_NNP 2_CD to_TO be_VB significantly_RB elevated_VBD
        above_IN controls_NNS ._. Elevations_NNP were_VBD independent_JJ of_IN stage_NN of_IN
        disease_NN or_CC tumor_NN histology_NN ._. Data_NNP also_RB show_NN mononuclear_NN
        phagocytes_NNS from_IN NSCLC_NNP patients_NNS produce_VBP significantly_RB more_JJR
        IL_NNP 10_CD over_IN 24_CD hr_NN in_IN primary_JJ culture_NN than_IN controls_NNS ,_,
        consistent_JJ with_IN reports_NNS of_IN altered_VBN cytokine_NN profiles_NNS of_IN
        adherent_NN mononuclear_NN cells_NNS from_IN breast_NN cancer_NN patients_NNS [_NN 29_CD
        ]_NN ._. Although_IN 
        in_IN vitro_NN experiments_NNS suggest_VBP there_EX
        could_MD be_VB a_DT direct_JJ link_NN between_IN elevated_JJ plasma_NN PGE-_NNP 2_CD levels_NNS
        and_CC increased_VBN IL_NNP 10_CD production_NN by_IN adherent_NN mononuclear_NN cells_NNS
        in_IN NSCLC_NNP ,_, the_DT measurements_NNS of_IN patient_NN samples_NNS do_VBP not_RB
        support_VB a_DT simple_JJ causal_NN relationship_NN ._. The_DT correlation_NN seen_VBN
        in_IN a_DT subset_NN of_IN 9_CD /_NN 11_CD patient_NN samples_NNS may_MD reflect_VB only_RB the_DT
        presence_NN of_IN underlying_VBG malignancy_NN ,_, however_RB ,_, it_PRP is_VBZ tempting_JJ
        to_TO speculate_VB on_IN the_DT physiologic_JJ relationship_NN between_IN the_DT
        two_CD ._.
        PGE-_NNP 2_CD can_MD be_VB induced_VBN by_IN a_DT number_NN of_IN inflammatory_JJ
        conditions_NNS ,_, however_RB no_DT single_JJ factor_NN ,_, other_JJ than_IN cancer_NN ,_, is_VBZ
        likely_JJ to_TO account_VB for_IN the_DT significant_JJ differences_NNS seen_VBN in_IN
        this_DT series_NN ._. Absolute_JJ values_NNS of_IN PGE-_NNP 2_CD ,_, that_WDT may_MD vary_VB with_IN
        different_JJ assays_NNS ,_, are_VBP likely_JJ less_RBR important_JJ than_IN the_DT
        observed_VBN differences_NNS between_IN NSCLC_NNP and_CC normals_NNS ._. The_DT lack_NN of_IN
        association_NN with_IN disease_NN stage_NN or_CC histology_NN ,_, and_CC the_DT
        nonspecific_JJ production_NN of_IN PGE-_NNP 2_CD by_IN multiple_JJ cell_NN types_NNS ,_, may_MD
        limit_VB the_DT usefulness_NN of_IN PGE-_NNP 2_CD as_IN a_DT specific_JJ ,_, independent_JJ
        marker_NN for_IN NSCLC_NNP ._.
        Apart_RB from_IN standardized_JJ measurement_NN of_IN PGE-_NNP 2_CD as_IN a_DT marker_NN
        for_IN disease_NN ,_, a_DT biologically_RB relevant_JJ aspect_NN of_IN elevated_VBD
        PGE-_NNP 2_CD would_MD be_VB in_IN the_DT association_NN with_IN altered_VBN immune_JJ
        profile_NN of_IN mononuclear_NN phagocytes_NNS ,_, specifically_RB IL_NNP 10_CD
        induction_NN ._. Importantly_NNP ,_, serum_NN IL_NNP 10_CD levels_NNS were_VBD established_VBN
        as_IN an_DT independent_JJ marker_NN for_IN disease_NN and_CC response_NN to_TO
        therapy_NN by_IN De_NNP Vita_NNP et_CC al_NN [_NN 10_CD ]_NN ._. The_DT source_NN of_IN the_DT IL_NNP 10_CD in_IN
        that_DT series_NN was_VBD thought_VBN to_TO be_VB from_IN mononuclear_NN cells_NNS ._. Based_VBN
        on_IN the_DT observations_NNS and_CC conclusions_NNS of_IN these_DT investigators_NNS ,_,
        and_CC the_DT measurable_JJ increases_NNS in_IN IL_NNP 10_CD production_NN by_IN
        mononuclear_NN phagocytes_NNS derived_VBN from_IN NSCLC_NNP patients_NNS compared_VBN
        to_TO controls_NNS ,_, plasma_NN levels_NNS of_IN IL_NNP 10_CD from_IN these_DT patients_NNS
        might_MD be_VB expected_VBN to_TO also_RB be_VB elevated_VBD ._. In_IN the_DT current_JJ
        series_NN ,_, however_RB ,_, there_EX was_VBD no_DT difference_NN between_IN patient_NN
        and_CC control_NN plasma_NN IL_NNP 10_CD levels_NNS ._. The_DT reasons_NNS for_IN this_DT
        discrepancy_NN are_VBP unclear_JJ ,_, and_CC may_MD be_VB related_VBN to_TO differences_NNS
        in_IN handling_VBG /_NN processing_NN samples_NNS or_CC differences_NNS in_IN the_DT
        sensitivity_NN of_IN the_DT ELISAs_NNP used_VBD in_IN the_DT studies_NNS ._. Further_RB ,_,
        there_EX was_VBD no_DT significant_JJ correlation_NN between_IN IL_NNP 10_CD
        production_NN by_IN mononuclear_NN cells_NNS and_CC disease_NN stage_NN ,_, as_IN might_MD
        be_VB inferred_VBN from_IN the_DT previously_RB mentioned_VBN studies_NNS ._. There_EX
        was_VBD no_DT correlation_NN with_IN histologic_JJ type_NN of_IN lung_NN cancer_NN ._.
      
      
        Conclusions_NNP
        Plasma_NNP PGE-_NNP 2_CD levels_NNS may_MD be_VB a_DT nonspecific_JJ marker_NN for_IN
        NSCLC_NNP and_CC warrants_NNS further_JJ investigation_NN ._. In_IN contrast_NN ,_,
        plasma_NN IL_NNP 10_CD levels_NNS did_VBD not_RB appear_VB to_TO be_VB sensitive_JJ markers_NNS
        in_IN our_PRP$ studies_NNS ;_: IL_NNP 10_CD production_NN by_IN circulating_VBG mononuclear_NN
        cells_NNS ,_, however_RB appears_VBZ to_TO be_VB associated_VBN with_IN disease_NN ._. The_DT
        reasons_NNS for_IN IL_NNP 10_CD production_NN by_IN mononuclear_NN cells_NNS in_IN NSCLC_NNP
        are_VBP speculative_JJ and_CC may_MD be_VB varied_VBN ._. Plasma_NNP PGE-_NNP 2_CD may_MD
        contribute_VB but_CC cannot_NN be_VB simply_RB and_CC directly_RB linked_VBN ._.
      
      
        Methods_NNP
        
          Cell_NNP lines_NNS
          Six_CD established_VBN NSCLC_NNP cell_NN lines_NNS (_( UKY-_NNP 104_CD ,_, NCI-_NNP 460_CD ,_,
          NCI-_NNP 820_CD ,_, NCI-_NNP 1155_CD ,_, NCI-_NNP 1355_CD ,_, and_CC A_DT 549_CD )_) were_VBD evaluated_VBN ._.
          Cell_NNP line_NN UKY-_NNP 104_CD is_VBZ an_DT adenocarcinoma_NN established_VBN in_IN
          primary_JJ culture_NN from_IN a_DT malignant_JJ pleural_NN effusion_NN ._. Cell_NNP
          lines_NNS NCI-_NNP 460_CD and_CC NCI-_NNP 1155_CD are_VBP large_JJ cell_NN carcinomas_NNS ,_,
          NCI-_NNP 820_CD is_VBZ a_DT bronchoalveolar_NN type_NN NSCLC_NNP ,_, NCI-_NNP 1355_CD is_VBZ an_DT
          adenocarcinoma_NN ,_, all_DT established_VBN at_IN the_DT National_NNP Cancer_NNP
          Institute_NNP (_( gift_NN of_IN H_NNP ._. Oie_NNP ,_, NCI_NNP ,_, National_NNP Institutes_NNPS of_IN
          Health_NNP ,_, Bethesda_NNP ,_, MD_NNP )_) ._. A_DT 549_CD is_VBZ an_DT undifferentiated_JJ lung_NN
          carcinoma_NN and_CC was_VBD purchased_VBN from_IN American_NNP Type_NNP Culture_NNP
          Collection_NNP (_( ATCC_NNP ,_, Rockville_NNP ,_, MD_NNP )_) ._. All_DT cells_NNS were_VBD
          maintained_VBN in_IN RPMI_NNP complete_JJ media_NNS (_( 10_CD %_NN fetal_JJ bovine_JJ
          serum_NN ,_, 50_CD units_NNS /_NN ml_NN penicillin_NN G_NNP and_CC 50_CD mg_NN /_NN ml_NN
          streptomycin_NN ;_: Gibco_NNP BRL_NNP Grand_NNP Island_NNP ,_, NY_NNP )_) ._. 293_CD ,_, a_DT human_JJ
          embryonic_JJ kidney_NN cell_NN line_NN was_VBD used_VBN as_IN a_DT control_NN ._.
        
        
          IL_NNP 10_CD production_NN by_IN adherent_NN PBMC_NNP from_IN normal_JJ
          donors_NNS
          Adherent_NNP monocytes_NNS ,_, derived_VBN from_IN whole_JJ blood_NN of_IN normal_JJ
          donors_NNS were_VBD purified_JJ from_IN peripheral_JJ blood_NN by_IN lysing_VBG red_JJ
          blood_NN cells_NNS using_VBG Red_NNP Blood_NNP Cell_NNP Lysis_NNP Solution_NN (_( Sigma_NNP ,_,
          St_NNP Louis_NNP ,_, MO_NNP )_) and_CC Ficoll_NNP Hypaque_NNP density_NN separation_NN
          technique_NN ._. Adherent_NNP mononuclear_NN cells_NNS were_VBD separated_JJ from_IN
          granulocytes_NNS and_CC nonadherent_NN mononuclear_NN cells_NNS (_( T_NN cells_NNS ,_,
          B_NNP cells_NNS Natural_NNP Killer_NNP cells_NNS )_) by_IN 4_CD hour_NN adherence_NN step_NN ._.
          10_CD 6_CD cells_NNS /_NN ml_NN were_VBD plated_JJ in_IN a_DT 24_CD well_RB culture_NN dish_NN for_IN 24_CD
          hr_NN in_IN tumor_NN cell_NN or_CC control_NN cell_NN conditioned_VBN media_NNS then_RB
          supernatants_NNS were_VBD assayed_JJ for_IN IL_NNP 10_CD by_IN ELISA_NNP
          (_( R_NN &_CC D_NNP )_) ._.
        
        
          Human_JJ subjects_NNS
          Following_VBG informed_VBN consent_NN ,_, peripheral_JJ blood_NN was_VBD
          obtained_VBN from_IN individuals_NNS with_IN histologically_RB confirmed_VBD
          NSCLC_NNP ._. None_NN of_IN the_DT subjects_NNS had_VBD concomitant_NN illness_NN such_JJ
          as_IN infection_NN and_CC none_NN of_IN the_DT subjects_NNS in_IN this_DT series_NN were_VBD
          taking_VBG anti-inflammatory_JJ medications_NNS ._.
        
        
          Plasma_NNP cytokines_NNS in_IN individuals_NNS with_IN NSCLC_NNP
          Plasma_NNP was_VBD separated_JJ from_IN cells_NNS by_IN centrifugation_NN and_CC
          cryopreserved_JJ at_IN -_: 80_CD °_NN until_IN use_NN ._. PGE-_NNP 2_CD and_CC IL_NNP 10_CD levels_NNS
          were_VBD measured_VBN in_IN 38_CD NSCLC_NNP patients_NNS and_CC compared_VBN to_TO that_DT
          from_IN healthy_JJ volunteers_NNS by_IN ELISA_NNP (_( R_NN &_CC D_NNP ,_, Minneapolis_NNP ,_,
          MN_NNP )_) ._. PGE-_NNP 2_CD levels_NNS were_VBD measured_VBN in_IN two_CD separate_JJ assays_NNS :_:
          the_DT first_JJ compared_VBN 38_CD NSCLC_NNP patient_NN samples_NNS to_TO 9_CD normals_NNS ;_:
          the_DT second_JJ compared_VBN 27_CD patient_NN samples_NNS to_TO a_DT different_JJ set_NN
          of_IN 16_CD normals_NNS ._. Stage_NN distribution_NN included_VBD 11_CD stage_NN I_PRP or_CC
          II_NNP ,_, 15_CD stage_NN IIIa_NNP /_NN b_SYM ,_, and_CC 13_CD stage_NN IV_NNP ._. Four_CD of_IN 10_CD stage_NN 4_CD
          patients_NNS donated_VBD blood_NN samples_NNS during_IN follow-up_JJ
          appointments_NNS in_IN between_IN cycles_NNS of_IN chemotherapy_NN ._. One_CD
          individual_NN was_VBD seen_VBN for_IN local_JJ recurrence_NN of_IN primary_JJ
          disease_NN (_( stage_NN IV_NNP )_) ,_, all_DT other_JJ samples_NNS were_VBD drawn_VBN at_IN the_DT
          time_NN of_IN initial_JJ diagnosis_NN ._. Histologies_NNP included_VBD 13_CD
          squamous_JJ cell_NN ,_, 12_CD adenocarcinoma_NN ,_, one_CD adeno_NN /_NN squamous_JJ
          cell_NN ,_, and_CC 12_CD unspecified_JJ NSCLC_NNP (_( undifferentiated_JJ or_CC
          poorly_RB differentiated_JJ non-small_JJ cell_NN carcinoma_NN )_) because_IN
          specific_JJ cell_NN type_NN was_VBD not_RB discernable_JJ from_IN available_JJ
          biopsies_NNS ._.
        
        
          Cytokine_NNP profile_NN of_IN adherent_NN PBMC_NNP from_IN individuals_NNS
          with_IN NSCLC_NNP
          In_IN 13_CD individual_JJ samples_NNS adequate_JJ numbers_NNS of_IN
          peripheral_JJ blood_NN mononuclear_NN cells_NNS were_VBD available_JJ for_IN
          processing_NN (_( stage_NN I-II_NNP n_NN =_SYM 3_CD ;_: stage_NN IIIa_NNP /_NN b_SYM n_NN =_SYM 6_CD ;_: stage_NN
          IV_NNP n_NN =_SYM 4_LS )_) ._. Adherent_NNP PBMC_NNP were_VBD purified_JJ from_IN peripheral_JJ
          blood_NN as_IN above_IN ._. 10_CD 6_CD adherent_NN mononuclear_NN cells_NNS /_NN ml_NN were_VBD
          incubated_JJ in_IN a_DT 24_CD well_RB culture_NN plate_NN in_IN complete_JJ RPMI_NNP and_CC
          supernatant_NN was_VBD evaluated_VBN at_IN 24_CD hr_NN for_IN basal_NN production_NN
          of_IN IL_NNP 10_CD by_IN ELISA_NNP (_( R_NN &_CC D_NNP )_) ._. Plasma_NNP and_CC mononuclear_NN cells_NNS
          were_VBD available_JJ for_IN evaluation_NN in_IN 11_CD of_IN 29_CD patient_NN plasma_NN
          samples_NNS ._.
        
        
          PGE-_NNP 2_CD production_NN by_IN established_VBN cell_NN lines_NNS in_IN vitro_NN
          and_CC generation_NN of_IN tumor_NN cell_NN conditioned_VBN media_NNS
          Tumor_NNP cell_NN lines_NNS or_CC control_NN cell_NN line_NN 293_CD were_VBD plated_JJ
          in_IN a_DT 24_CD well_RB culture_NN dish_NN (_( 5_CD ×_NN 10_CD 5_CD /_NN ml_NN )_) in_IN complete_JJ media_NNS
          ×_NN 24_CD hr_NN ._. Supernatants_NNP were_VBD assayed_JJ for_IN PGE-_NNP 2_CD by_IN ELISA_NNP
          (_( R_NN &_CC D_NNP )_) ._. Tumor_NNP cell_NN conditioned_VBN media_NNS (_( CM_NNP )_) was_VBD
          supernatant_NN of_IN cells_NNS cultured_JJ ×_NN 24_CD hr_NN in_IN RPMI_NNP complete_JJ
          media_NNS at_IN a_DT density_NN of_IN 5_CD ×_NN 10_CD 5_CD /_NN ml_NN ._. All_DT conditioned_VBN media_NNS
          was_VBD filtered_VBN through_IN a_DT 0_CD ._. 22_CD um_NN filter_NN prior_RB to_TO use_VB ._.
        
        
          Statistical_NNP analysis_NN
          Comparisons_NNP among_IN individual_JJ patient_NN samples_NNS were_VBD made_VBN
          using_VBG paired_VBN t-test_JJ and_CC all_DT other_JJ comparisons_NNS were_VBD made_VBN
          by_IN ANOVA_NNP ._.
        
      
      
        List_NN of_IN abbreviations_NNS
        Non-small_NNP cell_NN lung_NN cancer_NN (_( NSCLC_NNP )_) ;_: Prostaglandin_NNP E-_NNP 2_CD
        (_( PGE-_NNP 2_LS )_) ;_: Interleukin_NNP 10_CD (_( IL_NNP 10_CD )_) ;_: cytotoxic_JJ T_NN cell_NN (_( CTL_NNP )_)
      
      
        Authors_NNP '_'' contributions_NNS
        GH_NNP performed_VBD all_DT experiments_NNS ;_: LZ_NNP performed_VBD data_NNS analysis_NN
        and_CC assisted_VBN in_IN writing_VBG the_DT manuscript_NN ;_: DD_NNP participated_VBD
        with_IN extensive_JJ discussion_NN and_CC direction_NN in_IN experimental_JJ
        design_NN ;_: EH_NNP directed_VBD all_DT studies_NNS including_VBG gathering_VBG all_DT
        clinical_JJ samples_NNS ._. All_DT authors_NNS read_VBP and_CC approved_VBD the_DT final_JJ
        manuscript_NN
      
    
  
